CAR T cell therapy harnesses the immune system to seek out and kill tumor cells ... treating blood cancers is a phenomenon called 'antigen escape.' A key target for these therapies is a protein ...

These approaches include monoclonal antibodies against tumor antigens, checkpoint inhibitors that block tumors from accessing suppressive proteins on immune cells ... the possibility of tumor escape ...

An Indian biotech start-up led by a Kashmir scientist has a patented, 3rd-generation CAR-T therapy that targets cancer ...

This important work presents a stochastic branching process model of tumour-immune coevolution, incorporating stochastic antigenic mutation accumulation and escape within the cancer cell population.

Kanazawa University and colleagues have developed a promising new approach to cancer treatment. By using tiny, naturally ...

Cancer cells often have mutations that allow them to escape the immune system ... One example is CAR T cell therapy, which takes a patient’s T cells and adds a gene called a chimeric antigen receptor, ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have made a breakthrough in cancer ...

Initially designed for hematological malignancies, CAR-T therapy is now being expanded to target solid tumors using specialized CAR-T cells that attack specific antigens. Ongoing clinical trials are ...

or chimeric antigen receptor T-cell therapy, could be effective for treating Gavin’s type of brain cancer. The treatment programs a person’s own T cells — immune cells that usually fight ...

focusing on utilizing CD antigens as therapeutic targets for cancer treatment. CD antigens, or Cluster of Differentiation antigens, are cell surface proteins expressed on immune cells and tumor cells.